WO2000061141A3 - Methods and compositions for enhancing delivery of therapeutic agents to tissues - Google Patents

Methods and compositions for enhancing delivery of therapeutic agents to tissues Download PDF

Info

Publication number
WO2000061141A3
WO2000061141A3 PCT/US2000/009329 US0009329W WO0061141A3 WO 2000061141 A3 WO2000061141 A3 WO 2000061141A3 US 0009329 W US0009329 W US 0009329W WO 0061141 A3 WO0061141 A3 WO 0061141A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissues
therapeutic agents
methods
compositions
interior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/009329
Other languages
French (fr)
Other versions
WO2000061141A2 (en
Inventor
Jessie L-S Au
Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU42142/00A priority Critical patent/AU777620B2/en
Priority to CA002369263A priority patent/CA2369263A1/en
Priority to EP00921881A priority patent/EP1171118A2/en
Priority to JP2000610474A priority patent/JP2003524624A/en
Publication of WO2000061141A2 publication Critical patent/WO2000061141A2/en
Publication of WO2000061141A3 publication Critical patent/WO2000061141A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention, at least in part, is directed to methods for enhancing delivery of therapeutic agents, such as macromolecules and drugs, into the interior of tissues, such as solid tissues or tumors. The method initially uses an apoptosis inducing agent, such as paclitaxel, in doses which create channels within the tissues, and enhance the penetration of therapeutic agents to the interior of the tissue. Current methods of treating tissues are often not effective because the therapeutic agents are not delivered to the interior of the tissue. By using the methods and the compositions of the current invention, therapeutic agents can be delivered to the interior of the tissue.
PCT/US2000/009329 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues Ceased WO2000061141A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU42142/00A AU777620B2 (en) 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues
CA002369263A CA2369263A1 (en) 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues
EP00921881A EP1171118A2 (en) 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues
JP2000610474A JP2003524624A (en) 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12867499P 1999-04-09 1999-04-09
US60/128,674 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061141A2 WO2000061141A2 (en) 2000-10-19
WO2000061141A3 true WO2000061141A3 (en) 2001-03-01

Family

ID=22436437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009329 Ceased WO2000061141A2 (en) 1999-04-09 2000-04-07 Methods and compositions for enhancing delivery of therapeutic agents to tissues

Country Status (5)

Country Link
EP (1) EP1171118A2 (en)
JP (1) JP2003524624A (en)
AU (1) AU777620B2 (en)
CA (1) CA2369263A1 (en)
WO (1) WO2000061141A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1432402E (en) * 2001-10-03 2007-02-28 Celator Pharmaceuticals Inc Compositions for delivery of drug combinations
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
JP2004277379A (en) * 2003-03-18 2004-10-07 Medicos Hirata:Kk Drug delivery system for inducing apoptosis
JP4927535B2 (en) * 2003-04-03 2012-05-09 ジェシー エル エス オウ Particles encapsulating drugs that target tumors
US8043631B2 (en) * 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
BRPI0502497A (en) * 2005-06-28 2007-02-06 Univ Minas Gerais use of protein-coupled receptor agonists and antagonists, but as modulators of apoptotic activity for the study, prevention and treatment of diseases
WO2009116556A1 (en) * 2008-03-19 2009-09-24 富士フイルム株式会社 Pharmaceutical composition for injection
KR101208587B1 (en) * 2009-06-24 2012-12-06 여오영 Anticancer composition for local injection comprising hydroxychloroquine
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
MX348668B (en) * 2009-09-21 2017-06-23 J W Pharmaceutical Corp * Oxaliplatin nanoparticles and method for preparing same.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710134A (en) * 1994-05-20 1998-01-20 Behringwerke Aktiengesellschaft Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
WO1998032440A1 (en) * 1997-01-28 1998-07-30 The Procter & Gamble Company Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator
JPH11269065A (en) * 1998-03-19 1999-10-05 Microbial Chem Res Found Agent for overcoming apoptosis resistance of cancer cells
JPH11322602A (en) * 1998-05-13 1999-11-24 Kazuo Umezawa Transcription factor NFκB activation inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684709B2 (en) * 1992-05-20 1998-01-08 Pro-Neuron, Inc. Chemotherapeutic drug combinations
JP4619457B2 (en) * 1993-11-18 2011-01-26 シルテックス、メディカル、リミテッド Sustained release formulation
JP2001521503A (en) * 1997-03-31 2001-11-06 ネオルックス コーポレイション Therapeutic inhibitors of vascular smooth muscle cells
IL133585A0 (en) * 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710134A (en) * 1994-05-20 1998-01-20 Behringwerke Aktiengesellschaft Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
WO1998032440A1 (en) * 1997-01-28 1998-07-30 The Procter & Gamble Company Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator
JPH11269065A (en) * 1998-03-19 1999-10-05 Microbial Chem Res Found Agent for overcoming apoptosis resistance of cancer cells
JPH11322602A (en) * 1998-05-13 1999-11-24 Kazuo Umezawa Transcription factor NFκB activation inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200008, Derwent World Patents Index; Class B02, AN 2000-090993, XP002150249 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 01 31 January 2000 (2000-01-31) *
See also references of EP1171118A2 *

Also Published As

Publication number Publication date
EP1171118A2 (en) 2002-01-16
JP2003524624A (en) 2003-08-19
WO2000061141A2 (en) 2000-10-19
CA2369263A1 (en) 2000-10-19
AU777620B2 (en) 2004-10-21
AU4214200A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
CY1109661T1 (en) 5-CNAC AS AN AGENT FOR ADMINISTRATION OF ORAL PARAMETERS
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
WO2002041837A3 (en) Treatment of mucositis
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA03007837A (en) Compositions for delivering bisphosphonates.
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
WO2002076548A3 (en) Methods and apparatus for treating diseased tissue
NO20072167L (en) Combination comprising ZD6474 and an antiandrogen
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL138079A0 (en) 5-aminoindeno (1,2-c) pyrazol-4-ones as anti-cancer and anti-proliferative agents
BR0108728A (en) Pharmaceutical Combination Therapy, and, Method for Treating a Cancer.
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
EA200501166A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF THROMBOCYTHEMIA
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
WO2006086693A3 (en) Medical devices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369263

Country of ref document: CA

Ref country code: CA

Ref document number: 2369263

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610474

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921881

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000921881

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642